Piramal Pharma

200.30
-2.19
(-1.08%)
Market Cap
26,624.84 Cr
EPS
0.69
PE Ratio
302.24
Dividend Yield
0.07 %
Industry
Healthcare
52 Week High
307.90
52 Week Low
145.25
PB Ratio
3.31
Debt to Equity
0.60
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from9 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %

Company News

View All News
Caret
positive
Piramal Pharma's subsidiary has reached a settlement agreement with Astral, resulting in a $2.4 million payment to the Piramal unit. No further details about the nature of the settlement or the underlying dispute were provided in the given news snippet.
neutral
The Carlyle Group is planning to sell up to 10% of its stake in Piramal Pharma through block deals. This move indicates a significant change in Carlyle's investment position in the pharmaceutical company. Block deals are large-scale trades between two parties, typically conducted outside the open market.
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,665.60
#1 3,99,633.23
35.18
#1 54,729.00
12.06
#1 10,980
-18.99
48.33
6,926.50
1,83,876.81
83.40
9,360.00
0.89
2,117
23.05
68.54
1,492.40
1,20,542.32
23.71
28,409.50
7.12
5,291
30.28
54.26
3,322.50
1,12,448.50
59.20
11,539.40
11.59
1,911
10.91
62.08
1,281.90
1,06,983.67
#1 19.71
33,741.20
12.36
5,725
21.14
54.13
2,416.90
99,752.41
50.14
12,207.40
19.57
1,925
-10.91
59.65
975.10
98,117.88
21.52
22,573.80
13.82
3,977
-0.19
69.99
1,918.30
87,607.89
27.52
22,192.10
#1 19.94
3,024
#1 112.49
53.08
34,020.00
72,290.13
51.77
6,409.15
10.80
1,417
27.83
64.97
1,144.60
66,478.55
19.91
31,378.10
17.55
3,366
-0.50
63.70

Automatic Screeners on ScanX

Forecast
Actual
Growth Rate
Revenue Growth
14.23 %
Net Income Growth
-109.54 %
Cash Flow Change
-11.17 %
ROE
-108.36 %
ROCE
173.33 %
EBITDA Margin (Avg.)
40.67 %

Balance Sheet

Balance Sheet
2021
2022
2023
2024
2025
Total Assets
10,900
12,797
14,523
15,312
15,678
Fixed Assets
6,106
6,879
7,469
7,990
8,133
Current Assets
3,649
4,067
4,836
5,465
5,797
Capital Work in Progress
627
1,172
1,419
1,116
977
Investments
123
267
639
385
291
Other Assets
4,045
4,478
4,996
5,821
6,277
Total Liabilities
10,900
12,797
14,523
15,312
15,678
Current Liabilities
2,490
3,033
3,843
4,369
3,766
Non Current Liabilities
2,805
3,067
3,906
3,031
3,786
Total Equity
5,605
6,697
6,774
7,911
8,126
Reserve & Surplus
4,610
5,511
5,580
6,588
6,801
Share Capital
995
1,186
1,193
1,323
1,324

Cash Flow

Cash Flow
2021
2022
2023
2024
2025
Net Cash Flow
110
-177
-32
166
-37
Investing Activities
-4,464
-1,737
-1,334
-416
-488
Operating Activities
598
766
484
1,005
892
Financing Activities
3,977
794
818
-422
-441

Share Holding

% Holding
Sept 2022
Oct 2022
Dec 2022
Mar 2023
Jun 2023
Aug 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
34.79 %
0.00 %
34.79 %
34.79 %
34.79 %
35.02 %
35.02 %
35.02 %
35.02 %
34.95 %
34.95 %
34.95 %
34.95 %
FIIs
20.00 %
0.00 %
20.00 %
20.00 %
20.00 %
18.04 %
32.37 %
32.51 %
30.59 %
31.42 %
31.73 %
31.68 %
31.49 %
DIIs
4.86 %
0.00 %
5.28 %
4.99 %
5.49 %
7.83 %
8.02 %
9.68 %
12.12 %
12.95 %
13.81 %
14.10 %
14.78 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
7.42 %
0.00 %
11.80 %
13.94 %
16.77 %
16.81 %
16.95 %
15.57 %
15.13 %
13.94 %
13.29 %
13.29 %
13.11 %
Others
32.92 %
100.00 %
28.14 %
26.29 %
22.95 %
22.30 %
7.64 %
7.22 %
7.14 %
6.74 %
6.22 %
5.98 %
5.66 %
No of Share Holders
1,79,957
1,79,948
2,29,960
2,41,359
2,77,270
2,95,773
2,97,225
2,92,312
2,97,996
3,06,398
3,59,751
4,18,442
4,32,843

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 0.56 0.00 0.11 0.14
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.84 0.00 0.05 0.07

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
30 Jul 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
30 Jul 2025 200.22 202.49
16 Jul 2025 DIVIDEND Dividend
₹ 0.14 /share
16 Jul 2025 219.04 202.49
14 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 May 2025 211.96 219.04
28 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
28 Jan 2025 232.45 218.55
23 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
23 Oct 2024 219.85 217.99
26 Jul 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
26 Jul 2024 154.11 166.50
12 Jul 2024 DIVIDEND Dividend
₹ 0.11 /share
12 Jul 2024 150.45 151.10
02 Aug 2023 RIGHTS Rights
5:46
02 Aug 2023 106.01 102.95

Announcements

Company Update On Litigation3 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication4 days ago
Business Responsibility and Sustainability Reporting (BRSR)6 days ago
Notice Of The 5Th Annual General Meeting (AGM) And Annual Report For The Financial Year 2024-256 days ago
Reg. 34 (1) Annual Report.6 days ago
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 201110 days ago
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 26, 2025
Corporate Action-Board to consider DividendJun 13, 2025
Intimation Of Record Date For Payment Of Final DividendJun 13, 2025
Intimation Of 5Th Annual General Meeting To Be Held On Wednesday July 30 2025Jun 13, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (SEBI Listing Regulations)Jun 13, 2025
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sJun 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 02, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jun 02, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 26, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 21, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 16, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 15, 2025
Announcement under Regulation 30 (LODR)-Dividend UpdatesMay 14, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateMay 14, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 14, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 14, 2025
Audited Financial Results (Standalone & Consolidated) For The Quarter And Financial Year Ended 31St March 2025May 14, 2025
Board Meeting Outcome for Outcome Of Board Meeting Of Piramal Pharma Limited (Company) Held On 14Th May 2025May 14, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (SEBI Listing Regulations) - Capacity Expansion Of Lexington And Riverview SitesMay 12, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) -Successful Closure Of US FDA Inspection At Piramal PharmaS Manufacturing Facility Located At TurbheMay 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 29, 2025
Board Meeting Intimation for Board Meeting Intimation As Per Regulation 29 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)Apr 29, 2025
Announcement under Regulation 30 (LODR)-AcquisitionApr 23, 2025
Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations)Apr 01, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 21, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 20, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 11, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 20, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 19, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) -US FDA Inspection At Piramal PharmaS Facility Located At TurbhFeb 18, 2025
Intimation For Change In Domain Name And Generic E-Mail ID Of The Registrar And Share Transfer Agent (RTA) Of CompanyFeb 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 17, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Extension Of Timeline Communicated For Sale Of CompanyS Unit Situated At ThaneJan 31, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJan 30, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 30, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 29, 2025
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (SEBI Listing Regulations) - Issuance Of CorpJan 29, 2025
Integrated Filing (Financial)Jan 28, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJan 28, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 28, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateJan 28, 2025
Unaudited Financial Results (Standalone & Consolidated) For The Quarter And Nine Months Ended 31St December 2024Jan 28, 2025
Board Meeting Outcome for Outcome Of Board Meeting Of Piramal Pharma Limited (Company) Held On 28Th January 2025Jan 28, 2025

Technical Indicators

RSI(14)
Neutral
49.61
ATR(14)
Less Volatile
5.10
STOCH(9,6)
Neutral
79.09
STOCH RSI(14)
Overbought
84.46
MACD(12,26)
Bullish
0.88
ADX(14)
Weak Trend
19.50
UO(9)
Bearish
56.80
ROC(12)
Uptrend And Accelerating
5.45
WillR(14)
Neutral
-23.28

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
HDFC Flexi Cap Direct Plan-Growth
0.00%
-84585356
-2.30%
-2.32%
HDFC Focused Fund Direct-Growth
0.00%
-24000000
-2.53%
-2.73%
Canara Robeco Small Cap Fund Direct - Growth
0.00%
-6712333
-1.12%
-1.23%
HSBC Midcap Fund Direct-Growth
0.00%
-6480400
-1.17%
-1.28%
Bandhan Small Cap Fund Direct-Growth
0.00%
-3497423
-0.61%
-0.59%
Franklin India Opportunities Direct Fund-Growth
0.00%
-3407626
-1.02%
-1.11%
Canara Robeco Equity Hybrid Fund Direct-Growth
0.00%
-3150000
-0.59%
-0.62%
Canara Robeco ELSS Tax Saver Direct- Growth
0.00%
-2900000
-0.68%
-0.72%
HDFC Manufacturing Fund Direct - Growth
0.00%
-2400000
-0.41%
-0.43%
HDFC Pharma And Healthcare Fund Direct - Growth
0.00%
-1754783
-2.12%
-2.22%
Aditya Birla Sun Life Small Cap Fund Direct-Growth
0.00%
-1579446
-0.66%
-0.74%
Tata Flexi Cap Fund Direct - Growth
0.00%
-1500000
-0.95%
-1.34%
Canara Robeco Multi Cap Fund Direct - Growth
0.00%
-1406377
-0.68%
-0.93%
HDFC Business Cycle Fund Direct - Growth
0.00%
-1353894
-0.98%
-0.66%
Franklin India Multi Cap Fund Direct-Growth
0.00%
-1329470
-0.57%
-0.60%
ICICI Prudential Business Cycle Fund Direct - Growth
0.00%
-1197222
-0.19%
-0.20%
ICICI Prudential Midcap Direct Plan-Growth
0.00%
-1091460
-0.35%
-0.39%
ICICI Prudential Manufacturing Fund Direct - Growth
0.00%
-976877
-0.31%
-0.33%
LIC MF Flexi Cap Fund Direct-Growth
0.00%
-926813
-1.95%
-3.43%
Invesco India Manufacturing Fund Direct-Growth
0.00%
-874139
-2.22%
-2.39%
Canara Robeco Flexi Cap Fund Direct-Growth
0.00%
-834872
-0.13%
-0.20%
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth
0.00%
-734391
-0.67%
-0.75%
Edelweiss Business Cycle Fund Direct-Growth
0.00%
-693058
-0.78%
-0.83%
Mahindra Manulife Mid Cap Fund Direct - Growth
0.00%
-600000
-0.33%
-0.36%
Bajaj Finserv Healthcare Fund Direct-Growth
0.00%
-545316
-3.50%
-3.71%

About Piramal Pharma

Piramal Pharma Limited is an Indian pharmaceutical company incorporated in 2020. It offers a diverse portfolio of products and services through 17 global facilities and distribution in over 100 countries. The company operates through three main segments: an integrated Contract Development and Manufacturing Organization (CDMO) business, a Complex Hospital Generics (CHG) business, and an India Consumer Healthcare (ICH) business. Piramal Pharma Solutions provides integrated drug discovery, development, and manufacturing services. The company has a joint venture with Allergan in ophthalmology and a minority investment in Yapan Bio for biologics and vaccines. It is a leading player in India's self-care space with established brands. The company specializes in niche areas such as highly potent APIs, antibody drug conjugates, and biologics. In 2022, Piramal Pharma Limited was listed on the BSE and NSE following a demerger from Piramal Enterprises Limited.
Chairperson NameNandini Piramal